Actively Recruiting
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis
Led by Semmelweis University Heart and Vascular Center · Updated on 2024-11-22
150
Participants Needed
2
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this open label, randomized study is to compare the safety and efficacy of three different methods to handle coronary drug eluting stent (DES) in-stent restenosis (ISR). These are the: * Magic Touch - sirolimus coated balloon * Emperor - paclitaxel and dextran coated balloon * Xience - chromium-cobalt everolimus eluting stent
CONDITIONS
Official Title
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted for intervention of drug eluting stent restenosis
- Restenosis suitable for all three treatment arms as per 'instructions for use' of the devices
- Optional enrollment in the optical coherence tomography sub-study (10-20% of patients)
You will not qualify if you...
- Patients undergoing coronary angiography after sudden cardiac death
- Pregnant or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Semmelweis University Heart and Vascular Center
Budapest, Budapest, Hungary, 1122
Actively Recruiting
2
University of Szeged, Department of Invasive Cardiology
Szeged, Csongád-Csanád, Hungary, 6725
Actively Recruiting
Research Team
I
István F Édes, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here